NYP-Brooklyn-Methodist-Hospital-Welcomes-New-Years-Baby-of-2019
At 12:44 a.m. on January 1, NewYork-Presbyterian Brooklyn
Methodist Hospital welcomed its New Year’s Baby, Joseph Patrick Bernstein.
NYP-WD-Achieves-Designation-from-ANCC-Magnet-Recognition-Program
NewYork-Presbyterian Westchester Division announced today that it has received national recognition for excellence in nursing from the American Nurses Credentialing Center’s (ANCC) Magnet Recognition Program®, the highest and most prestigious distinction that a health care organization can earn for nursing excellence and innovation.
Dr-Hidalgo-Named-Chief-Hematology-and-Medical-Oncology-WCM-NYPWC
Dr. Manuel Hidalgo, a leading physician-scientist who specializes in pancreatic cancer and drug development, has been named chief of the Division of Hematology and Medical Oncology in the Weill Department of Medicine at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, effective June 1. Dr. Hidalgo will also serve on the leadership team at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine.
New-Smart-Drug-for-Metastatic-Triple-Negative-Breast-Cancer
A clinical trial at NewYork-Presbyterian/Columbia and other centers found that patients responded to a new “smart drug” for women with an aggressive form of breast cancer.
NYP-Splunk-Implement-New-Approach-to-Guard-Against-Opioid-Misuse
Splunk Inc. (NASDAQ: SPLK), delivering actions and outcomes from the world of data, and NewYork-Presbyterian, one of the nation’s most comprehensive academic healthcare delivery systems, are collaborating to help solve one of the toughest challenges in healthcare.
NYP-Wins-Two-Best-and-Brightest-Awards-2019
NewYork-Presbyterian Hospital recently won two Best and Brightest awards from the National Association for Business Resources (NABR). In 2018, NewYork-Presbyterian Hospital was recognized as one of the Best and Brightest Companies to Work For and was among the Best and Brightest in Wellness.
Immunotherapy-May-Help-Patients-with-Advanced-Esophageal-Cancer
Treating patients with advanced, metastatic esophageal cancer with an immune-system boosting drug called pembrolizumab, known by its brand name Keytruda, led to regression of tumors in some patients, according to results of a phase 2 clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators.
Hepatitis-Common-in-New-Cancer-Patients
A multicenter study from SWOG Cancer Research Network found that infections with hepatitis B and C are common in new cancer patients, but few of these patients are screened for these viruses.
Page49 of 167